AR061873A1 - Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. - Google Patents
Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas.Info
- Publication number
- AR061873A1 AR061873A1 ARP070103070A ARP070103070A AR061873A1 AR 061873 A1 AR061873 A1 AR 061873A1 AR P070103070 A ARP070103070 A AR P070103070A AR P070103070 A ARP070103070 A AR P070103070A AR 061873 A1 AR061873 A1 AR 061873A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heteroaryl
- aryl
- alkyl
- aryl heteroaryl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- -1 amino, substituted amino Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 6
- 125000001589 carboacyl group Chemical group 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 4
- 150000001408 amides Chemical class 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 3
- 125000001118 alkylidene group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 3
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 3
- XIKRJRRZTIMYRY-UHFFFAOYSA-N (cyanosulfonylamino)urea Chemical class NC(=O)NNS(=O)(=O)C#N XIKRJRRZTIMYRY-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000005239 aroylamino group Chemical group 0.000 abstract 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000005325 aryloxy aryl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical class NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 abstract 2
- 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) donde Q1 es arilo, arilo sustituido, heteroarilo o heteroarilo sustituido, X es C=O, C=S, C=NR9 o CH2; R1, R2, y R3 son independientemente seleccionados de H, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, hidroxi, alcoxi, alcoxi sustituido, halogeno, haloalquilo, haloalcoxi, alcanoilo, alcanoilo sustituido, amino, amino sustituido, aminoalquilo, aminoalquilo sustituido, alquilamino, alquilamino sustituido, amida, amida sustituida, carbamato, ureido, ciano, sulfonamido, sulfonamido sustituido, alquilsulfona, nitro, tio, tioalquilo, alquiltio, diamino sustituido, alquilsulfonilo, alquilsulfinilo, carboxi, alcoxicarbonilo, alquilcarboniloxi, carbamoilo, carbamoilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, y alquilcarbonilo; R4 es H, alquilo, alquilo sustituido, hidroxi, alcoxi, halogeno, haloalquilo, haloalcoxi, oxo, ariloxi, arilalquilo, arilalquiloxi, alcanoilo, alcanoilo sustituido, alcanoiloxi, amino, amino sustituido, aminoalquilo, aminoalquilo sustituido, alquilamino, alquilamino sustituido, hidroxialquilo, diamino sustituido, amida, amida sustituida, carbamato, carbamato sustituido, ureido, ciano, sulfonamida, sulfonamida sustituida, alquilsulfona, heterocicloalquilo, heterocicloalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloalquenilo, cicloalquenilo sustituido, cicloalquilalquilo, cicloalquilalcoxi, nitro, tio, tioalquilo, alquiltio, alquilsulfonilo, alquilsulfinilo, carboxi, alcoxicarbonilo, alquilcarboniloxi, carbamoilo, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heteroariloxi, arilheteroarilo, arilalcoxicarbonilo, heteroarilalquilo, heteroarilalcoxi, ariloxialquilo, ariloxiarilo, heterociclo, heterociclo sustituido, alquilcarbonilo, heteroalquilo sustituido, heteroalquenilo, heteroalquenilo sustituido, heteroalquinilo, heteroalquinilo sustituido, arilamino, arilalquilamino, alcanoilamino, aroilamino, arilalcanoilamino, ariltio, arilalquiltio, arilsulfonilo, arilalquilsulfonilo, alquilsulfonilo, arilcarbonilamino, o alquilaminocarbonilo; R5 se selecciona de hidrogeno, halogeno, ciano, alquilo o alquilo substituido; R6 es independientemente seleccionado de hidrogeno, alquilo, alquilo sustituido, alquilideno, alquilideno sustituido, hidroxi, alcoxi, halogeno, haloalquilo, haloalcoxi, oxo, ariloxi, arilalquilo, arilalquiloxi, alcanoilo, alcanoilo sustituido, alcanoiloxi, amino, aminoalquilo, aminoalquilo sustituido, alquilamino, alquilamino sustituido, hidroxialquilo, diamino sustituido, amida, amida sustituida, carbamato, carbamato sustituido, ureido, ciano, sulfonamida, sulfonamida sustituida, alquilsulfona, heterocicloalquilo, heterocicloalquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloalquenilo, cicloalquenilo sustituido, cicloalquilalquilo, cicloalquilalcoxi, nitro, tio, tioalquilo, alquiltio, alquilsulfonilo, alquilsulfinilo, carboxi, alcoxicarbonilo, alquilcarboniloxi, carbamoilo, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heteroariloxi, arilheteroarilo, arilalcoxicarbonilo, heteroarilalquilo, heteroarilalcoxi, ariloxialquilo, ariloxiarilo, heterociclo, heterociclo sustituido, alquilcarbonilo, heteroalquilo sustituido, heteroalquenilo, heteroalquenilo sustituido, heteroalquinilo, heteroalquinilo sustituido, arilamino, arilalquilamino, alcanoilamino, aroilamino, arilalcanoilamino, ariltio, arilalquiltio, arilsulfonilo, arilalquilsulfonilo, alquilsulfonilo, arilcarbonilamino, o alquilaminocarbonilo; n es 0, 1, 2, 3, 4, 5 o 6; o cuando n = 2 y R6 son sustituyentes geminales juntos pueden formar un anillo carbocíclico o heterocíclico saturado o no saturado de 3-6 miembros opcionalmente sustituido; o cuando n = 2 y R6 son sustituyentes 1,2-cis, juntos pueden formar un anillo carbocíclico o heterocíclico fusionado saturado de 3-6 miembros opcionalmente sustituido; o cuando n = 2, y R6 son sustituyentes 1,3-cis juntos pueden formar un puente de alquilo o heteroalquilo de 1-4 miembros opcionalmente sustituido; o cuando hay dos R6 en el mismo C, estos pueden formar un grupo carbonilo (C=O) o alquilideno (C=CHR9); y R7 y R8 son independientemente seleccionados de H, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroalquenilo, heteroalquenilo sustituido, heteroalquinilo o heteroalquinilo sustituido, o R7 y R8 pueden juntos formar un anillo carbocíclico o heterocíclico saturado o no saturado de 4-8 miembros opcionalmente substituido, o un anillo carbocíclico o heterocíclico saturado o no saturado de 7-12 miembros bicíclico opcionalmente substituido; R9 es hidrogeno o. alquilo inferior; o una sal, tautomero o estereoisomero farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81917106P | 2006-07-07 | 2006-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061873A1 true AR061873A1 (es) | 2008-09-24 |
Family
ID=38671050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103070A AR061873A1 (es) | 2006-07-07 | 2007-07-10 | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7534792B2 (es) |
| EP (1) | EP2041138B1 (es) |
| JP (1) | JP5185930B2 (es) |
| KR (1) | KR101443400B1 (es) |
| CN (1) | CN101511835B (es) |
| AR (1) | AR061873A1 (es) |
| AU (1) | AU2007269163B2 (es) |
| BR (1) | BRPI0714359A2 (es) |
| CA (1) | CA2657594C (es) |
| CL (1) | CL2007001995A1 (es) |
| CO (1) | CO6220940A2 (es) |
| DK (1) | DK2041138T3 (es) |
| EA (1) | EA018322B1 (es) |
| ES (1) | ES2493566T3 (es) |
| HR (1) | HRP20140688T1 (es) |
| IL (1) | IL196033A0 (es) |
| MX (1) | MX2008016517A (es) |
| NO (1) | NO342385B1 (es) |
| NZ (1) | NZ574189A (es) |
| PE (1) | PE20080677A1 (es) |
| PL (1) | PL2041138T3 (es) |
| PT (1) | PT2041138E (es) |
| SI (1) | SI2041138T1 (es) |
| TW (1) | TWI393722B (es) |
| WO (1) | WO2008005956A2 (es) |
| ZA (1) | ZA200900109B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008015457A (es) * | 2006-07-07 | 2009-01-16 | Boehringer Ingelheim Int | Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales. |
| PL2041138T3 (pl) * | 2006-07-07 | 2014-11-28 | Bristol Myers Squibb Co | Pirolotriazyny jako inhibitory kinazy |
| JP5319659B2 (ja) * | 2007-04-18 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2176249A2 (en) * | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
| PE20090837A1 (es) * | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| CN102015719A (zh) * | 2008-03-06 | 2011-04-13 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| EP2350052B1 (en) | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
| JP5592890B2 (ja) * | 2008-10-08 | 2014-09-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
| EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
| JP2013518889A (ja) * | 2010-02-03 | 2013-05-23 | ブリストル−マイヤーズ スクイブ カンパニー | （Ｓ）−１−（４−（５−シクロプロピル−１Ｈ−ピラゾール−３−イルアミノ）ピロロ［１，２−ｆ］［１，２，４］トリアジン−２−イル）−Ｎ−（６−フルオロピリジン−３−イル）−２−メチルピロリジン−２−カルボキサミドの結晶形 |
| JP5093527B2 (ja) * | 2010-02-10 | 2012-12-12 | 日本電気株式会社 | 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路 |
| WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| WO2011123493A1 (en) | 2010-03-31 | 2011-10-06 | Bristol-Myers Squibb Company | Substituted pyrrolotriazines as protein kinase inhibitors |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| CN102584828B (zh) * | 2011-01-14 | 2016-01-27 | 上海艾力斯医药科技有限公司 | 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用 |
| US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| EP2752410B1 (en) | 2011-10-25 | 2016-08-31 | Shionogi & Co., Ltd. | Heterocycle derivative having pgd2 receptor antagonist activity |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9422267B2 (en) | 2012-12-26 | 2016-08-23 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015057873A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
| WO2015126808A2 (en) * | 2014-02-18 | 2015-08-27 | Baldwin John J | Hbv assay |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| CN104974163B (zh) * | 2014-04-14 | 2017-11-07 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
| EP3475281A1 (en) * | 2016-06-23 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| JP7098630B2 (ja) | 2017-01-10 | 2022-07-11 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| EP3392267A1 (en) | 2017-04-18 | 2018-10-24 | Myr GmbH | Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| EP3654952A1 (en) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| SMT202300447T1 (it) | 2019-04-12 | 2024-01-10 | Blueprint Medicines Corp | Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione |
| TWI857043B (zh) | 2019-04-12 | 2024-10-01 | 美商纜圖藥品公司 | 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法 |
| CA3141424C (en) * | 2019-06-14 | 2023-11-07 | Zhengxia CHEN | Fused ring compound as fgfr and vegfr dual inhibitor |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| HRP20250814T1 (hr) | 2020-07-02 | 2025-09-12 | Incyte Corporation | Spojevi tricikličke uree kao jak2 v617f inhibitori |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| AR124442A1 (es) * | 2020-12-21 | 2023-03-29 | Biocryst Pharm Inc | Regímenes de dosificación de inhibidores orales de alk2 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| KR102612407B1 (ko) * | 2021-01-14 | 2023-12-11 | 환인제약 주식회사 | Ｂｍｓ－７５４８０７ 화합물을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물 |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CN112679407B (zh) * | 2021-03-17 | 2021-06-04 | 南京桦冠生物技术有限公司 | 一种手性5-取代脯氨酸类化合物的制备方法 |
| KR20240099221A (ko) * | 2021-09-29 | 2024-06-28 | 리페어 세라퓨틱스 인크. | N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (티아졸릴)])(치환된)카복스아마이드 화합물 및 인간 중합효소 세타를 저해하기 위한 이의 용도 |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| KR20250007533A (ko) | 2022-04-08 | 2025-01-14 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물 |
| EP4594316A1 (en) * | 2022-09-29 | 2025-08-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
| CN116178358B (zh) * | 2022-11-04 | 2024-04-19 | 济南大学 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
| TW202509078A (zh) | 2023-07-07 | 2025-03-01 | 美商維里迪恩醫療股份有限公司 | 治療慢性甲狀腺眼病之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100666514B1 (ko) | 1999-05-21 | 2007-02-28 | 브리스톨-마이어즈 스퀴브 컴페니 | 키나제의 피롤로트리아진 저해제 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| PL2041138T3 (pl) * | 2006-07-07 | 2014-11-28 | Bristol Myers Squibb Co | Pirolotriazyny jako inhibitory kinazy |
| ES2393410T3 (es) * | 2006-08-09 | 2012-12-21 | Bristol-Myers Squibb Company | Pirrolotriazinas inhibidoras de quinasas |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5180967B2 (ja) * | 2006-11-03 | 2013-04-10 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
-
2007
- 2007-07-03 PL PL07799265T patent/PL2041138T3/pl unknown
- 2007-07-03 NZ NZ574189A patent/NZ574189A/en unknown
- 2007-07-03 CA CA2657594A patent/CA2657594C/en not_active Expired - Fee Related
- 2007-07-03 PT PT77992659T patent/PT2041138E/pt unknown
- 2007-07-03 WO PCT/US2007/072697 patent/WO2008005956A2/en not_active Ceased
- 2007-07-03 DK DK07799265.9T patent/DK2041138T3/da active
- 2007-07-03 JP JP2009519588A patent/JP5185930B2/ja not_active Expired - Fee Related
- 2007-07-03 KR KR1020097002487A patent/KR101443400B1/ko not_active Expired - Fee Related
- 2007-07-03 HR HRP20140688TT patent/HRP20140688T1/hr unknown
- 2007-07-03 EA EA200900152A patent/EA018322B1/ru not_active IP Right Cessation
- 2007-07-03 EP EP07799265.9A patent/EP2041138B1/en active Active
- 2007-07-03 CN CN2007800327558A patent/CN101511835B/zh not_active Expired - Fee Related
- 2007-07-03 SI SI200731488T patent/SI2041138T1/sl unknown
- 2007-07-03 ES ES07799265.9T patent/ES2493566T3/es active Active
- 2007-07-03 MX MX2008016517A patent/MX2008016517A/es active IP Right Grant
- 2007-07-03 AU AU2007269163A patent/AU2007269163B2/en not_active Ceased
- 2007-07-03 BR BRPI0714359-1A patent/BRPI0714359A2/pt active Search and Examination
- 2007-07-05 US US11/773,466 patent/US7534792B2/en active Active
- 2007-07-05 PE PE2007000874A patent/PE20080677A1/es active IP Right Grant
- 2007-07-06 TW TW096124588A patent/TWI393722B/zh not_active IP Right Cessation
- 2007-07-06 CL CL2007001995A patent/CL2007001995A1/es unknown
- 2007-07-10 AR ARP070103070A patent/AR061873A1/es not_active Application Discontinuation
-
2008
- 2008-12-18 IL IL196033A patent/IL196033A0/en active IP Right Grant
-
2009
- 2009-01-05 NO NO20090025A patent/NO342385B1/no not_active IP Right Cessation
- 2009-01-06 ZA ZA200900109A patent/ZA200900109B/xx unknown
- 2009-01-06 CO CO09000765A patent/CO6220940A2/es active IP Right Grant
- 2009-03-26 US US12/411,724 patent/US7879855B2/en active Active
-
2011
- 2011-01-28 US US13/015,687 patent/US8263765B2/en active Active
-
2012
- 2012-08-07 US US13/568,750 patent/US8592579B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061873A1 (es) | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| RU2424240C2 (ru) | Антибактериальные производные пиперидина | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CO5680435A2 (es) | Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
| AR046308A1 (es) | Derivados amida | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR039648A1 (es) | Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen | |
| AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen | |
| RU2008112205A (ru) | Сульфонамидное соединение | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| RU2015105561A (ru) | Замещенные гетероазепиноны | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| PE20081492A1 (es) | Derivados de sulfonamida heterociclicos como antagonista de edg-1 | |
| MX2007007428A (es) | Compuestos heterociclicos, antagonistas de ccr2b. | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
| AR045694A1 (es) | Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion | |
| PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| DE60014404D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| PE20090280A1 (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |